ArticleOncotarget2018

Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment.

Sinead A Noonan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.